Concepedia

Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam

Stephanie Katzenmaier, Christoph Markert, Gerd Mikus

European Journal of Clinical Pharmacology · 2010 · 35 citations · 10 references

DOIFull text

Open access

Abstract

The determination of the partial AUC using four plasma samples from 2 to 4 h after oral administration of a midazolam solution is proposed to be an easy and reliable CYP3A phenotyping measure which of course needs to be validated in prospective clinical trials.

References

10

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism*

Kenneth E. Thummel, Diarmuid O’Shea, Mary F. Paine et al. · Clinical Pharmacology & Therapeutics · 1996 · 616 citations

Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping

Bettina Link, Manuel Haschke, Nathalie Grignaschi et al. · British Journal of Clinical Pharmacology · 2008 · 73 citations · Full text

A limited sampling strategy for cyclophosphamide pharmacokinetics.

Merrill J. Egorin, Alan Forrest, Chandra P. Belani · PubMed · 1989 · 69 citations

, , +9

Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4‐dimethyl‐benziso‐(2H)‐selenazine (ALT‐2074), an experimental catalytic mimic of glutathione oxidase

David J. Greenblatt, Diane E. Peters, Lauren Oleson et al. · British Journal of Clinical Pharmacology · 2009 · 61 citations · Full text

Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity

Verena Häfner, Michael Jäger, A-K Matthée et al. · Clinical Pharmacology & Therapeutics · 2009 · 56 citations